BACKGROUND AND PURPOSE: Blood-brain barrier disruption and consequent vasogenic edema formation codetermine the clinical course of intracerebral hemorrhage (ICH). This study examined the effect of PHA-543613, a novel α7 nicotinic acetylcholine receptor agonist, on blood-brain barrier preservation after ICH. METHODS: Male CD-1 mice, subjected to intrastriatal blood infusion, received PHA-543613 alone or in combination with α7 nicotinic acetylcholine receptor antagonist methyllycaconitine or phosphatidylinositol 3-kinase inhibitor wortmannin. RESULTS: PHA-543613 alone, but not in combination with methyllycaconitine or wortmannin, inhibited glycogen synthase kinase-3β, thus, stabilizing β-catenin and tight junction proteins, which was paralleled by improved blood-brain barrier stability and ameliorated neurofunctional deficits in ICH animals. CONCLUSIONS: PHA-543613 preserved blood-brain barrier integrity after ICH, possibly through phosphatidylinositol 3-kinase-Akt-induced inhibition of glycogen synthase kinase-3β and β-catenin stabilization.
BACKGROUND AND PURPOSE: Blood-brain barrier disruption and consequent vasogenic edema formation codetermine the clinical course of intracerebral hemorrhage (ICH). This study examined the effect of PHA-543613, a novel α7 nicotinic acetylcholine receptor agonist, on blood-brain barrier preservation after ICH. METHODS: Male CD-1mice, subjected to intrastriatal blood infusion, received PHA-543613 alone or in combination with α7 nicotinic acetylcholine receptor antagonist methyllycaconitine or phosphatidylinositol 3-kinase inhibitor wortmannin. RESULTS:PHA-543613 alone, but not in combination with methyllycaconitine or wortmannin, inhibited glycogen synthase kinase-3β, thus, stabilizing β-catenin and tight junction proteins, which was paralleled by improved blood-brain barrier stability and ameliorated neurofunctional deficits in ICH animals. CONCLUSIONS:PHA-543613 preserved blood-brain barrier integrity after ICH, possibly through phosphatidylinositol 3-kinase-Akt-induced inhibition of glycogen synthase kinase-3β and β-catenin stabilization.
Authors: James M Gebel; Edward C Jauch; Thomas G Brott; Jane Khoury; Laura Sauerbeck; Shelia Salisbury; Judith Spilker; Thomas A Tomsick; John Duldner; Joseph P Broderick Journal: Stroke Date: 2002-11 Impact factor: 7.914
Authors: Crystal L MacLellan; Gergely Silasi; Candice C Poon; Carmen L Edmundson; Richard Buist; James Peeling; Frederick Colbourne Journal: J Cereb Blood Flow Metab Date: 2007-08-29 Impact factor: 6.200
Authors: Stefan Liebner; Monica Corada; Thorsten Bangsow; Jane Babbage; Andrea Taddei; Cathrin J Czupalla; Marco Reis; Angelina Felici; Hartwig Wolburg; Marcus Fruttiger; Makoto M Taketo; Harald von Melchner; Karl Heinz Plate; Holger Gerhardt; Elisabetta Dejana Journal: J Cell Biol Date: 2008-10-27 Impact factor: 10.539
Authors: Li Li; Devin W McBride; Desislava Doycheva; Brandon J Dixon; Paul R Krafft; John H Zhang; Jiping Tang Journal: Exp Neurol Date: 2015-01-10 Impact factor: 5.330
Authors: Richard F Keep; Anuska V Andjelkovic; Jianming Xiang; Svetlana M Stamatovic; David A Antonetti; Ya Hua; Guohua Xi Journal: J Cereb Blood Flow Metab Date: 2018-05-08 Impact factor: 6.200
Authors: Paul R Krafft; Devin W McBride; Tim Lekic; William B Rolland; Charles E Mansell; Qingyi Ma; Jiping Tang; John H Zhang Journal: Behav Brain Res Date: 2014-02-08 Impact factor: 3.332